

#### US006015835A

# **United States Patent** [19]

# Miyamoto et al.

[11] Patent Number: 6,015,835

[45] Date of Patent: Jan. 18, 2000

### [54] METHODS OF INDUCING ANALGESIA OR ANESTHESIA AND TREATING OR PREVENTING ISCHEMIC INJURY OF TISSUES IN GENERAL

[75] Inventors: Tadaomi Miyamoto, Kitakyushu; Koho Miyamoto, Okinawa-ken, both of Japan

[73] Assignee: Meddiss, Incorporated, Fukuoka,

Japan

[21] Appl. No.: **09/028,482** 

[22] Filed: Feb. 24, 1998

### Related U.S. Application Data

[63] Continuation-in-part of application No. 08/622,606, Mar. 26, 1996, abandoned.

[51] Int. Cl.<sup>7</sup> ...... A01N 37/12

[52] **U.S. Cl.** ...... **514/562**; 514/578; 514/665

### [56] References Cited

### U.S. PATENT DOCUMENTS

5,084,007	1/1992	Malin et al.	604/20
5,084,482	1/1992	Hirsch et al.	514/562

#### FOREIGN PATENT DOCUMENTS

 $2\ 051\ 789 \quad 1/1981 \quad United\ Kingdom\ .$ 

## OTHER PUBLICATIONS

Schrader et al., Adenosine and Adenine Nucleotides as Regulators of Cellular Function, "Intracellular pathways involved in the formation of adenosin", 1995, pp. 5–13. Rudolphi et al., Cerebrovascular and Brain Metabolism Reviews, vol. 4, 1992, pp. 346–369, "Adenosine and Brain Ischemia".

Lehmann et al., Neuroscience Letters, vol. 52, 1984, pp. 341–346, "A role for taurine in the maintenance of homeostasis in the central nervous system during yperexcitation". Schubert et al., Acta Neurochir, vol. 57(Suppl.), 1993, pp. 80–88, "Cerebral protection by Adenosine".

S. Budavari, The Merck Index, 11<sup>th</sup> Edition, p. 943, entry 5896 and pp. 1433–1434, entry 9043, 1989, "Methitural". J.E.F. Reynolds, Martindale, The Extra Pharmacopoeia, 29<sup>th</sup> Edition, pp. 843 and 1621, 1989, "Methionine and Racemethionine" and "Taurine".

Chemical Abstracts of Japan, vol. 96, No. 155452e, Ruggero G. Fariello, et al., Neurology, vol. 32, pp. 241, Mar. 1982, "Homotaurine (3 Aminopropanesulfonic Acid, 3APS) Protects Form the Convulsant and Cytotoxic Effect of Systemically Administered Kainic Acid".

Henrik Hagberg et al, "Ischemia-Induced Shift of Inhibitory and Excitatory Amino Acids from Intra- to Extracellular Compartments", *Journal of Cerebral Blood Flow and Metabolism*, vol. 5, No. 1, Mar. 1985, pp. 413–419, XP000675093.

Henrik Hagberg et al, "Extracellular overflow of glutamate, aspartate, GABA and taurine in the cortex and basal ganglia of fetal lambs during hypoxia-ischemia", *Neuroscience Letters*, vol. 78, No. 3, Aug. 1987, pp. 311–317, XP000675088.

D. Lekieffre et al, "Concomitant increases in the extracellular concentrations of excitatory and inhibitory amino acids in the rat hippocampus during forebrain ischemia", *Neuroscience Letters*, vol. 137, 1992, pp. 78–82, XP000677297.

David W. Busija et al, "Dilator effects of amino acid neurotransmitters on piglet pial arterioles", *American Journal of Physiology*, vol. 257, No. 4, Part 2, Oct. 1989, pp. H1200–H1203, XP000675109.

Carl S. Hornfeldt et al, "Antinociceptive Effects of Intrathecal Taurine and Calcium in the Mouse", *Life Sciences*, vol. 50, No. 24, 1992, pp. 1925–1934, XP000675107.

David B. Masters et al, "Release of amino acids into regional superfusates of the spinal cord by mechano stimulation of the reproductive tract", *Brain Research*, vol. 621, No. 2, 1993, pp. 279–290, XP000675094.

David H. Smullin et al, "Interactions between substance P, calcitonin gene-related peptide, taurine and excitatory amino acids in the spinal cord", *Pain*, vol. 42, No. 1, 1990, pp. 93–101, XP000675202.

Carlos Beyer et al, "Blockage of Substance P-Induced Scratching Behavior in Rats by the Intrathecal Administration of Inhibitory Amino Acid Agonists", *Pharmacology Biochemistry and Behavior*, vol. 34, No. 3, 1989, pp. 491–495, XP000677502.

Carlos Beyer et al, "Prevention of the Convulsant and Hyperalgesic Action of Strychnine by Intrathecal Glycine and Related Amino Acids", *Pharmacology Biochemistry and Behavior*, vol. 29, No. 1, 1988, pp. 73–78, XP000677503.

Avital Schurr et al, "Pharmacological Protection Against Cerebral Hypoxia by Taurine in vitro", *Elsevier Science Publishers B.V.*, 1986, pp. 363–370, XP000677851.

Primary Examiner—Dwayne C. Jones Attorney, Agent, or Firm—Oblon, Spivak, McClelland, Maier & Neustadt, P.C.

#### [57] ABSTRACT

The invention relates to methods for inducing analgesia (or even anesthesia) and for prevention or amelioration of damage caused by ischemic or traumatic injury of tissues in general, but especially neural, for the central nervous system being the most vulnerable of all tissues, by the systemic administration of a therapeutically effective amount of primarily taurine, and secondarily homotaurine and/or methionine for a sufficient period of time (several hours to a few days, depending on the severity of the injury, and timing when therapy is initiated from the time of injury) to allow recovery from the original insult or from phenomena that follow the initial injury.

# 12 Claims, 7 Drawing Sheets